CoChat

Cyclooxygenase-1 and -2 in the Different Stages of Alzheimers Disease Pathology

Hoozemans, J., Rozemuller, J., van Haastert, E., Veerhuis, R., Eikelenboom, P. · 2008 · Current Pharmaceutical Design

The DOI matches its Crossref record.

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the deposition of beta amyloid (Abeta) protein and the formation of neurofibrillary tangles. In addition, there is an increase of inflammatory proteins in the brains of AD patients. Epidemiological studies, indicating that non-steroidal anti-inflammatory drugs (NSAIDs) decrease the risk of developing AD, have encouraged the study on the role of inflammation in AD. The best-characterized action of most NSAIDs is the inhibition of cyclooxygenase (COX). The expression of the constitutively expressed COX-1 and the inflammatory induced COX-2 has been intensively investigated in AD brain and different disease models for AD. Despite these studies, clinical trials with NSAIDs or selective COX-2 inhibitors showed little or no effect on clinical progression of AD. The expression levels of COX-1 and COX-2 change in the different stages of AD pathology. In an early stage, when low-fibrillar Abeta deposits are present and only very few neurofibrillary tangles are observed in the cortical areas, COX-2 is increased in neurons. The increased neuronal COX-2 expression parallels and colocalizes with the expression of cell cycle proteins. COX-1 is primarily expressed in microglia, which are associated with fibrillar Abeta deposits. This suggests that in AD brain COX-1 and COX-2 are involved in inflammatory and regenerating pathways respectively. In this review we will discuss the role of COX-1 and COX-2 in the different stages of AD pathology. Understanding the physiological and pathological role of cyclooxygenase in AD pathology may facilitate the design of therapeutics for the treatment or prevention of AD.

Overview

Integrity signals

Registry

Crossref · 10.2174/138161208784480171

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Still being checked.

Cited by

See all 137

Metadata

Authors
Hoozemans, J., Rozemuller, J., van Haastert, E., Veerhuis, R., & Eikelenboom, P.
Affiliations
Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
Venue
Current Pharmaceutical Design
Published
2008-05-01
Volume
14
Issue
14
Pages
1419-1427
ISSN
1381-6128 (ISSN-L)
OpenAlex
W2138214629
Cited by
137
References
0
Citations by year
2026: 4 · 2025: 5 · 2024: 8 · 2023: 12 · 2022: 10 · 2021: 4 · 2020: 7 · 2019: 4 · 2018: 5 · 2017: 3 · 2016: 6 · 2015: 5 · 2014: 7 · 2013: 9 · 2012: 10
FWCI
8.80
Type
journal article
Language
en
Open access
closed
Locations
  • Current Pharmaceutical Design (publishedVersion)
  • PubMed (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion)
Funders
Vrije Universiteit Amsterdam
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
Keywords
Alzheimer's disease, cyclooxygenase-1, cyclooxygenase-2, amyloid-beta, neurofibrillary tangles, neuroinflammation, microglia, cell cycle proteins, nonsteroidal anti-inflammatory drugs, COX-2 inhibitors, disease stage, neurodegeneration
MeSH terms
Alzheimer Disease, Anti-Inflammatory Agents, Non-Steroidal, Humans, Inflammation, Neurons, Amyloid beta-Peptides, Cyclooxygenase Inhibitors, Cell Cycle Proteins, Cyclooxygenase 1, Cyclooxygenase 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cyclooxygenase-1 and -2 in the Different Stages of Alzheimers Disease Pathology. https://app.cochat.ai/papers/10.2174/138161208784480171
The paper
Hoozemans, J., Rozemuller, J., van Haastert, E., Veerhuis, R., & Eikelenboom, P. (2008). Cyclooxygenase-1 and -2 in the Different Stages of Alzheimers Disease Pathology. Current Pharmaceutical Design. https://doi.org/10.2174/138161208784480171

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.